Cargando…

Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach

Major depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD. In this study, a proteomic method was used to identify a new MDD biomarker. Using sequential window acquisition of al...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hyebin, Mun, Sora, Joo, Eun-Jeong, Lee, Kyu Young, Kang, Hee-Gyoo, Lee, Jiyeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002827/
https://www.ncbi.nlm.nih.gov/pubmed/33802981
http://dx.doi.org/10.3390/diagnostics11030539
_version_ 1783671542970843136
author Choi, Hyebin
Mun, Sora
Joo, Eun-Jeong
Lee, Kyu Young
Kang, Hee-Gyoo
Lee, Jiyeong
author_facet Choi, Hyebin
Mun, Sora
Joo, Eun-Jeong
Lee, Kyu Young
Kang, Hee-Gyoo
Lee, Jiyeong
author_sort Choi, Hyebin
collection PubMed
description Major depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD. In this study, a proteomic method was used to identify a new MDD biomarker. Using sequential window acquisition of all theoretical mass spectra acquisitions and multiple reaction monitoring analysis via mass spectrometry, relative and absolute quantification of proteins in the sera was performed. The results of the relative quantitation by sequential window acquisition for all theoretical mass spectra data showed that seven proteins were significantly differently expressed between MDD patients and other patients with remission status. However, absolute quantification by multiple reaction monitoring analysis identified prothrombin as the only significantly upregulated protein in the depressive state compared to remission (p < 0.05) and was, thus, subsequently selected as an MDD biomarker. The area under the curve for prothrombin was 0.66. Additionally, increased prothrombin/thrombin induced hyper-activation of platelets via activating protease-activated receptors, a feature associated with MDD; specifically, activated platelets secrete various molecules related to MDD, including brain-derived neurotropic factors and serotonin. Therefore, prothrombin is a potential screening, prognostic, and diagnostic marker for MDD.
format Online
Article
Text
id pubmed-8002827
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80028272021-03-28 Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach Choi, Hyebin Mun, Sora Joo, Eun-Jeong Lee, Kyu Young Kang, Hee-Gyoo Lee, Jiyeong Diagnostics (Basel) Article Major depressive disorder (MDD) is a common disorder involving depressive mood and decreased motivation. Due to its high heterogeneity, novel biomarkers are required to diagnose MDD. In this study, a proteomic method was used to identify a new MDD biomarker. Using sequential window acquisition of all theoretical mass spectra acquisitions and multiple reaction monitoring analysis via mass spectrometry, relative and absolute quantification of proteins in the sera was performed. The results of the relative quantitation by sequential window acquisition for all theoretical mass spectra data showed that seven proteins were significantly differently expressed between MDD patients and other patients with remission status. However, absolute quantification by multiple reaction monitoring analysis identified prothrombin as the only significantly upregulated protein in the depressive state compared to remission (p < 0.05) and was, thus, subsequently selected as an MDD biomarker. The area under the curve for prothrombin was 0.66. Additionally, increased prothrombin/thrombin induced hyper-activation of platelets via activating protease-activated receptors, a feature associated with MDD; specifically, activated platelets secrete various molecules related to MDD, including brain-derived neurotropic factors and serotonin. Therefore, prothrombin is a potential screening, prognostic, and diagnostic marker for MDD. MDPI 2021-03-17 /pmc/articles/PMC8002827/ /pubmed/33802981 http://dx.doi.org/10.3390/diagnostics11030539 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Choi, Hyebin
Mun, Sora
Joo, Eun-Jeong
Lee, Kyu Young
Kang, Hee-Gyoo
Lee, Jiyeong
Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
title Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
title_full Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
title_fullStr Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
title_full_unstemmed Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
title_short Discovery of Screening Biomarkers for Major Depressive Disorder in Remission by Proteomic Approach
title_sort discovery of screening biomarkers for major depressive disorder in remission by proteomic approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002827/
https://www.ncbi.nlm.nih.gov/pubmed/33802981
http://dx.doi.org/10.3390/diagnostics11030539
work_keys_str_mv AT choihyebin discoveryofscreeningbiomarkersformajordepressivedisorderinremissionbyproteomicapproach
AT munsora discoveryofscreeningbiomarkersformajordepressivedisorderinremissionbyproteomicapproach
AT jooeunjeong discoveryofscreeningbiomarkersformajordepressivedisorderinremissionbyproteomicapproach
AT leekyuyoung discoveryofscreeningbiomarkersformajordepressivedisorderinremissionbyproteomicapproach
AT kangheegyoo discoveryofscreeningbiomarkersformajordepressivedisorderinremissionbyproteomicapproach
AT leejiyeong discoveryofscreeningbiomarkersformajordepressivedisorderinremissionbyproteomicapproach